Karyopharm 2025 Q3 Earnings Revenue Surpasses Estimates Despite Widening Net Loss

Karyopharm Therapeutics (KPTI) reported Q3 2025 earnings on Nov 4, 2025, with revenue rising 13.6% to $44.04 million, outpacing estimates of $41.21 million. However, the net loss widened to $33.13 million, up 3.3% from $32.07 million in the prior-year quarter. The company reaffirmed full-year revenue guidance of $140–155 million but reduced R&D/SG&A expenses to $235–245 million.

Revenue

Product revenue, net, led the performance with $32.03 million, driven by 8.5% year-over-year growth in XPOVIO sales. License and other revenue contributed an additional $12.01 million, reflecting milestone-related income from international partners. The total revenue of $44.04 million underscored the company’s ability to expand market access and diversify revenue streams despite ongoing operational challenges.

Earnings/Net Income

The company narrowed its loss per share to $3.82, a 0.8% improvement from $3.85 in 2024 Q3. However, the net loss expanded to $33.13 million, indicating persistent financial pressures despite modest EPS progress.

Post-Earnings Price Action Review

Karyopharm’s stock faced immediate headwinds, with shares dropping 5.83% on the day of the report, 10.74% over the subsequent week, and 11.44% month-to-date. Historical data suggests a pattern of short-term underperformance following revenue beats, attributed to high short interest (~25% of float). While 30-day returns averaged -5.2% across 10 revenue beat events since 2015, long-term catalysts like XPOVIO’s 8.5% YoY growth and the Phase 3 SENTRY trial completion in March 2026 offer potential upside. Investors remain cautious, balancing near-term liquidity constraints against pipeline advancements. <visualization dataurl="https://cdn.ainvest.com/news/visual/visual_components/viz_xw25wobx.json"></visualization>

Additional News

Karyopharm granted 800 restricted stock units to a newly hired employee on Oct 31, 2025, under its 2022 inducement plan, reflecting strategic talent acquisition efforts. The company reaffirmed full-year 2025 revenue guidance of $140–155 million and U.S. XPOVIO sales targets of $110–120 million, while narrowing R&D/SG&A expenses to $235–245 million. Additionally, the Phase 3 SENTRY myelofibrosis trial, which enrolled 353 patients, completed enrollment in Q3 2025, with top-line data expected in March 2026—a critical milestone for regulatory and commercial pathways. These updates highlight operational progress amid financial constraints.

CEO Commentary

The CEO emphasized XPOVIO’s growth trajectory and global access expansion, noting that U.S. net product revenue rose 8.5% year-over-year. Strategic priorities included cost management, with R&D/SG&A expenses reduced to $235–245 million for 2025, and leveraging partnerships like Menarini to boost international revenue. The leadership team expressed cautious optimism about the SENTRY trial’s potential to unlock new indications, while acknowledging the need to balance near-term liquidity with long-term innovation.

Guidance

Karyopharm reaffirmed full-year 2025 total revenue guidance of $140–155 million and U.S. XPOVIO revenue of $110–120 million. The company also narrowed R&D/SG&A expense projections to $235–245 million, reflecting disciplined cost control. Forward-looking expectations include the March 2026 SENTRY trial readout and potential FDA approval for diffuse large B-cell lymphoma (DLBCL), which could redefine market access and revenue streams.

(text2img/)